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Abstract
Background: Fas (Apo-1/CD95) and its specific ligand (FasL) are key elements in apoptosis. They have been studied in 
different malignancies but there are few published studies about the soluble forms of these markers (i.e. sFas/sFasL) in 
gastric cancer. We have compared the serum levels of sFas/sFasL in gastric adenocarcinoma patients and cases with 
pre-neoplastic lesions as potential markers for early diagnosis, and investigated their relation with clinicopathological 
characteristics.
Methods: Fifty-nine newly-diagnosed cases of gastric adenocarcinoma who had undergone gastrectomy, along with 
62 endoscopically- and histologically-confirmed non-cancer individuals were enrolled in this study. sFas/sFasL serum 
levels were detected by Enzyme Linked Immunosurbent Assay.
Results: Mean serum sFas level was significantly higher in gastric cancer patients than in control group (305.97 ± 63.71 
(pg/ml) vs. 92.98 ± 4.95 (pg/ml), P < 0.001); while the mean serum level of sFasL was lower in patients with gastric 
adenocarcinoma (0.138 ± 0.04 (pg/ml) vs. 0.150 ± 0.02 (pg/ml), P < 0.001). Mean serum levels of sFas/sFasL were 
significantly different in both intestinal/diffuse and cardiac/non-cardiac subtypes when compared to the control group 
(P < 0.001). There was an increase in the serum level of sFas from the first steps of pre-neoplastic lesions to gastric 
adenocarcinoma (P < 0.001). Patients who had no lymph node involvement (N0) showed significantly higher serum 
levels of sFas compared to others (P = 0.044).
Conclusions: Production of sFas may play a critical role in the carcinogenesis of intestinal-type gastric cancer. sFas 
serum level may serve as a non-invasive tool for early diagnosis of gastric cancer.
Background
Gastric cancer is the second leading cause of cancer-
related mortality worldwide with a great geographic vari-
ation[1]. In Iran, it is the second most common cancer in
males and the forth in females. It has been estimated that
gastric cancer is the most common cause of cancer-asso-
ciated mortality in Iranian population[2].
Although gastric cancer has a poor prognosis with a
five-year survival rate of 25% in the United States[3],
there is no standard biomarker for early diagnosis and no
consensus on screening programs. To date, some guide-
lines have been proposed for early diagnosis[1] and new
molecular markers and therapeutic strategies are
required to design effective diagnostic and therapeutic
protocols.
Derailment of apoptosis plays an important role in the
development, growth and resistance of malignant
tumors, and also influences the prognosis[4]. As a mem-
ber of TNF-family receptors, Fas (Apo-1/CD95) is a cell
surface protein that can induce apoptosis through its
cytosolic tail after binding to its specific ligand, Fas
Ligand[5]. Fas and Fas Ligand (FasL) are crucial in
immune system homeostasis[6,7]. FasL is also a major
weapon for cytolytic T cells to induce apoptosis in tumor
cells[4]. Consequently, a decrease in Fas expression in the
membrane of tumor cells can protect them from this
lethal influence of FasL. FasL detection on the cell surface
of some tumor cells proposed the hypothesis that these
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cells can escape immune attack through induction of
apoptosis in tumor infiltrating lymphocytes[8,9]. The Fas
gene produces two protein isoforms through alternative
mRNA splicing: the full-length Fas which contains a
trans-membrane domain, and the soluble form of Fas
(sFas), which lacks this domain. Soluble Fas acts as a
decoy in the extra-cellular environment and binds
FasL[10,11]. Therefore, there is an immune privilege for
tumor cells by secretion of sFas as an inhibitor of apopto-
sis.
Fas/FasL system has been investigated in a large variety
of neoplasms[12-15]. However, few studies have been
reported about gastric cancer to date. Previous studies
indicate that gastric carcinomas express FasL at a higher
level, while lower level of Fas expression leads to evade
the killing effects of host immune system[16-18]. There
are some conflicting reports about the correlations of
Fas/FasL expression--studied by immunohistochemistry
(IHC) method--and tumor size, depth of invasion, metas-
tasis, differentiation and Lauren's classification of gastric
tumors [18,19]. Few studies have been published about
the serum level of sFas/sFasL in gastric cancer, with dis-
crepancies in their results[20-23].
This study was conducted to assess the serum level of
sFas/sFasL in gastric adenocarcinoma and non-tumoral
lesions, to find their possible role in early diagnosis and
their correlations with clinicopathological features of this
malignancy.
Methods
Sample collection
Study included fifty-nine patients with newly-diagnosed,
histologically-confirmed gastric adenocarcinoma, who
were admitted to the department of surgery in Omid
Oncology Hospital, Mashhad, Iran; between February
2006 and June 2008. Patients with unresectable tumors,
history of previous chemotherapy, radiation therapy, or
gastric surgery were excluded. Sixty-two individuals were
enrolled in the control group. They had all undergone
esophagogastrodeodenoscopy due to upper gastrointesti-
nal complaints in the endoscopy unit, Imam Reza Univer-
sity Hospital, Mashhad, Iran; and were proven to have no
endoscopic and histological evidence of gastric tumor.
The study protocol was approved by the Research Eth-
ics Committee in Mashhad University of Medical Sci-
ences. A written informed consent was obtained from
each individual. Demographic characteristics (e.g. ethnic-
ity, age, and gender) and clinical data including symp-
toms, medications, and potential risk factors were
obtained via a questionnaire filled by trained personnel.
These risk factors included history of tobacco consump-
tion and family history of gastric cancer.
According to updated Sydney System[24], five biopsies
were obtained from each individual in the control group
for histological examination: two from the antrum, two
from the corpus, and one from the incisura angularis.
Another antral biopsy was obtained for the detection of
H. pylori via a commercially available Rapid Urease Test
(Chemenzyme Co., Iran). Biopsy samples were fixed in
10% buffered formalin. After routine tissue processing,
they were examined for the presence of five pathologic
variables including density of H. pylori, intensity of neu-
trophilic and mononuclear inflammation, atrophy, intes-
tinal metaplasia, and dysplasia. We divided the control
group into three subgroups according to the pathologic
pattern: mild gastritis without H. pylori infection (named
as near-normal mucosa), chronic gastritis with H. pylori
infection (chronic active gastritis), and precancerous
lesions (including chronic atrophic gastritis, gastric atro-
phy, intestinal metaplasia, and dysplasia). Giemsa stain-
ing was applied in suspicious cases for better evaluation
of H. pylori.
In the cancer group, the histological diagnosis was
based on morphological examination of the samples that
were routinely processed and stained with hematoxylin
and eosin method. According to Lauren's criteria, tumors
were classified as intestinal and diffuse type. Tumor grade
and surgical stage were determined as well.
Enzyme Linked Immunosurbent Assay (ELISA)
A 3-ml sample of venous blood was collected from each
participant before endoscopy or one day before surgery,
in control and cancer groups, respectively. Immediately
after blood sampling, serum was obtained by centrifuga-
tion at 2000 r/min for 15 min at 4°C and stored at -20°C
until subsequent assay. The titres of H. pylori IgG anti-
body were measured via commercial ELISA (Padtan Elm
Co., Ltd. Iran), according to the manufacturer's instruc-
tions. Serum levels of sFas and sFasL were assessed using
human ELISA kits (Bender MedSystems, GmbH, Vienna,
Austria) according to the manufacturer's instructions.
Statistical analysis
C h i -s q ua r e  t es t  wi t h  9 5 %  c o n fi d e n c e  i n t e rva l  was  pe r -
formed for comparing the variables. As serum levels of
sFas and sFasL did not have a normal distribution, we
used Kruskal-Wallis and Mann-Whitney U tests to com-
pare the mean serum levels of sFas and sFasL in different
groups. Data have been shown as mean ± SEM (standard
error of mean) in ures and tables. The statistical analyses
were performed using the SPSS 16.0 statistical package
(SPSS, Inc, Chicago, IL, USA).
Results
Forty-four out of 59 patients with gastric adenocarci-
noma were male (M/F ratio: 2.93). The median age was
62 years (ranging from 39 to 79, mean: 60.25 ± 10). Of 62
individuals in the non-tumoral group, 32 were males andBoroumand-Noughabi et al. BMC Cancer 2010, 10:275
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30 were females with a median age of 47 years (ranging
from 20 to 77, mean: 47.32 ± 16). Poor economic status,
lower level of education and tobacco consumption were
significantly more prevalent in cancer group (p < 0.05).
Most of our patients were diagnosed as intestinal type
gastric cancer (45/59), of which 10, 15 and 5 were well,
moderately and poorly differentiated carcinomas, respec-
tively, and in 5 cases, the grade of differentiation was
unknown. Among 62 non-cancer individuals 11 were cat-
egorized as near-normal mucosa, 35 as chronic active
gastritis and in 16 cases, precancerous lesions were seen
in the stomach. Based on laboratory exams, 73.6% of our
cancer patients had a positive history of H. pylori infec-
tion, while in the control group this positive history was
found in 82.3%.
Mean serum levels of sFas/sFasL based on descriptive
characteristics of the non-tumoral and tumoral groups
are summarized in table 1 and table 2. There was a posi-
tive correlation between tobacco smoking and mean
serum level of sFas, but not sFasL, among non-tumoral
group (P = 0.041). However, in the tumoral group, no
association was observed between smoking and mean
serum level of sFas/sFasL (P = 0.06 for sFas). There was
no significant difference in serum levels of sFas/sFasL
between cases with or without history of H. pylori infec-
tion in either tumoral or non-tumoral groups.
The mean serum level of sFas was significantly higher
in gastric cancer patients than control group (P < 0.001),
while the mean serum level of sFasL was lower in patients
with gastric adenocarcinoma (P < 0.001). After grouping
the patients by histological type (intestinal/diffuse) and
tumor location (cardia/non-cardia), there were statisti-
cally significant differences in serum sFas/sFasL level in
all of the subgroups versus non-tumoral group (Table 3).
An increasing gradient for mean serum level of sFas
was observed, from normal mucosa toward gastric cancer
(Kruskal-Wallis test, P < 0.001). Analysis showed a signif-
icant difference between serum level of sFas in each non-
tumoral subgroup and cancer group (Figure 1), (tumoral
Table 1: Serum levels of sFas/sFasL based on descriptive characteristics of non-tumoral group
Non-Tumoral Group
sFas (pg/ml) sFasL (pg/ml)
N* Mean ± SE.M† P Value N* Mean ± SE.M† P Value
Gender
Male 30 103.21 ± 7.54 0.023 32 0.13 ± 0.02 0.09
Female 29 82.40 ± 5.88 30 0.17 ± 0.03
Economic Status\
Poor 15 85.21 ± 11.66 0.82 16 0.10 ± 0.03 0.17
Moderate to Good 43 95.07 ± 5.45 45 0.16 ± 0.02
Educational Status
Under high school Diploma 41 97.94 ± 6.44 0.25 43 0.16 ± 0.03 0.91
High school Diploma & above 16 81.42 ± 6.91 17 0.13 ± 0.02
Tobacco consumption
Negative 51 88.83 ± 5.03 0.041 53 0.16 ± 0.02 0.11
Positive 8 119.46 ± 15.27 9 0.11 ± 0.01
Opium addiction
Negative 46 86.81 ± 5.20 0.015 47 0.16 ± 0.02 0.52
Positive 13 114.82 ± 11.31 15 0.12 ± 0.02
History of H. pylori infection‡
Negative 49 76.17 ± 9.76 0.12 51 0.14 ± 0.04 0.27
Positive 10 97.74 ± 5.58 11 0.15 ± 0.02
* N: Number of samples
† Mean ± SE.M: Mean Serum Range ± Standard Error of Mean
‡ History of H. pylori infection: Based on laboratory dataBoroumand-Noughabi et al. BMC Cancer 2010, 10:275
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vs. normal: P < 0.001; tumoral vs. chronic active gastritis:
P < 0.001; tumoral vs. precancerous lesions: P = 0.009).
Serum level of sFas/sFasL and their correlation with
clinicopathological features of the tumors are represented
in Table 4. Although serum level of sFasL was signifi-
cantly lower in cardiac type of tumor versus non-cardiac
type (P = 0.005), serum level of sFas was not significantly
associated to tumor location (cardia vs. non-cardia).
There was no correlation between serum levels of sFas/
sFasL and different histopathologic subtypes of adenocar-
cinoma (intestinal vs. diffuse), tumor grade of differentia-
t io n a nd sta g e of  t um or .  P a t ie n ts  wit h no lym ph node
metastasis (N0) had significantly higher levels of sFas than
those with lymph node involvement (N1-3) (P = 0.044).
Discussion
Gastric cancer is the second leading cause of cancer-
related deaths worldwide. It is diagnosed in advanced
stages in the majority of cases and no efficient therapeu-
tic modality has been suggested to overcome the problem
of treatment resistance yet. Gastric adenocarcinoma has
a complex network of molecular alterations along its car-
cinogenesis pathway. Despite numerous studies focused
on this issue, many crucial questions still remain to be
clarified. Discovery of these molecular changes can be
translated into efficient diagnostic and therapeutic
modalities and be employed for targeting the cancer like
in some other malignancies[25,26]. Apoptosis-regulating
genes play a critical role in carcinogenesis. Fas/FasL sys-
tem exerts a central role in the apoptosis process and its
alterations are noticeable in gastric adenocarcinoma.
Although there are some studies indicating that gastric
carcinomas express higher levels of FasL and lower levels
of Fas to evade the killing effects of host immune sys-
tem[16-18], there are only few reports addressing their
soluble forms.
While Yatsuya et al reported significant difference in
serum concentration of sFas only between female gastric
cancer patients and controls[23], Liang et al represented
a significantly higher serum level of sFas in all patients
Table 2: Serum levels of sFas/sFasL based on descriptive characteristics of patients with gastric adenocarcinoma
Gastric Adenocarcinoma Group
sFas (pg/ml) sFasL (pg/ml)
N* Mean ± SE.M† P Value N* Mean ± SE.M† P Value
Gender
Male 41 348.89 ± 85.04 0.55 44 0.16 ± 0.06 0.28
Female 15 188.63 ± 4.54 15 0.06 ± 0.04
Economic Status
Poor 24 222.94 ± 45.98 0.93 26 0.05 ± 0.02 0.006
Moderate to Good 20 279.68 ± 104.11 21 0.20 ± 0.11
Educational Status
Under high school Diploma 38 262.75 ± 61.03 0.33 41 0.08 ± 0.03 0.018
High school Diploma & above 4 129.93 ± 35.48 4 0.60 ± 0.54
Tobacco consumption
Negative 28 234.81 ± 76.62 0.06 29 0.07 ± 0.03 0.34
Positive 15 281.3 ± 65.87 17 0.22 ± 0.13
Opium addiction
Negative 46 282.55 ± 64.73 0.37 49 0.15 ± 0.05 0.47
Positive 10 413.67 ± 202.46 10 0.10 ± 0.06
History of H. pylori infection‡
Negative 34 390.46 ± 145.66 0.64 37 0.10 ± 0.04 0.13
Positive 15 182.09 ± 21.08 15 0.14 ± 0.07
* N: Number of samples
† Mean ± SE.M: Mean Serum Range ± Standard Error of Mean
‡ History of H. pylori infection: Based on laboratory dataBoroumand-Noughabi et al. BMC Cancer 2010, 10:275
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with gastric cancer compared to non-tumoral individu-
als[21], similar to our results. To explain the observation
of decrease in Fas and increase in serum level of sFas in
gastric cancer[17,21], we hypothesize that translational
processing of the Fas gene in gastric tumoral cells may be
deranged leading to the production of mostly soluble,
rather than membranous, Fas. Possibly , mRNA splicing
phase alternates toward producing higher levels of sFas
with lower molecular weight rather than full-length
(membranous) F as. T hus, we conclude that changes in
Fas gene expression may be a part of sequential events in
the multistep process of gastric cancer development.
To confirm this idea, a group of non-tumoral cases,
consisting of various pathologic lesions of non-precan-
cerous and precancerous lesions from different levels of
multistep carcinogenesis pathway, were evaluated for
serum levels of sFas and sFasL. The findings indicated an
increasing gradient in the level of sFas from normal
through tumoral epithelium. Analysis showed a signifi-
cant difference between sFas level in each noncancerous
subgroup and cancer group; in line with the findings of Li
et al[27]. With the application of IHC and western-blot
hybridization methods, they reported increasing fre-
quencies of Fas expression in progression from non-can-
cerous to cancerous mucosa (6.3% in normal mucosa,
60% in atrophic gastritis, 75% in intestinal metaplasia,
100% in grades 2 and 3 dysplasia and gastric adenocarci-
noma). They found that soluble Fas (30 KD), but not the
membrane type (43 KD), was predominantly expressed in
the Fas-positive cases[27]. By quantitatively measuring
the increased levels of sFas in serum, we suggest that pro-
duction of sFas is a crucial event in gastric carcinogene-
sis. In addition, the significant difference between the
serum levels in gastric cancer patients and precancerous
group, and also the increases along the carcinogenesis
pathway may introduce sFas as a useful, cost-effective,
and non-invasive biomarker for early detection of gastric
cancer. Further studies with larger sample size are
required to establish a precise cut-off point for that pur-
pose. Tamakoshi A et al performed a nested case-control
study within a large-scale prospective study and sug-
gested that serum sFas has a possibility to detect people
at high risk for cancer (regardless of cancer type) prior to
diagnosis[15].
We found a significantly higher serum level of sFasL in
patients with non-cardiac type of gastric cancer versus
those with cardiac type (P = 0.005). To our knowledge,
there is no published study addressing the serum levels of
sFas/sFasL in cardiac and non-cardiac types of gastric
cancer. Our results may confirm the differences in the
carcinogenesis pathway and molecular alterations of
these subgroups of gastric tumors. Further studies are
required to clarify the role of sFas/sFasL in gastric car-
cinogenesis in cardiac versus non-cardiac tumors.
Some studies reported elevated concentrations of
serum sFasL in patients with various types of malignan-
cies and concluded that sFasL may be derived from can-
cer cells as a result of high expression of FasL gene[28-
30]. Others have shown lower levels of sFasL in cancer
p a t i e n t s  c o m p a r e d  t o  c o n t r o l s ,  s u g g e s t i n g  t h a t  s e r u m
sFasL is possibly consumed by binding to Fas expressed
on activated circulating CD8+T lymphocytes[31,32]. In
gastric cancer, there are few reports with controversial
findings to date. Yoshikawa et al showed lower level of
sFasL in serum of patients with gastric cancer than nor-
mal controls[32], while significantly higher level of sFasL
Table 3: Comparison of serum levels of sFas and sFasL in different subgroups of gastric adenocarcinoma with non-tumoral 
group
sFas (pg/ml) sFasL (pg/ml)
N* Mean ± SE.M† P Value N* Mean ± SE.M† P Value
Gastric Cancer Group (vs. Non-Tumoral) (vs. Non-Tumoral)
Overall 56 305.97 ± 63.71 < 0.001 59 0.138 ± 0.04 < 0.001
Intestinal 43 293.06 ± 73.88 < 0.001 45 0.147 ± 0.05 < 0.001
Diffuse 13 348.61 ± 129.43 < 0.001 14 0.109 ± 0.05 < 0.001
Cardia 18 242.72 ± 62.78 0.001 18 0.026 ± 0.01 < 0.001
Non-cardia 37 358.92 ± 99.61 < 0.001 40 0.206 ± 0.07 < 0.001
Non-Tumoral Group 59 92.98 ± 4.95 62 0.150 ± 0.02
* N: Number of samples
† Mean ± SE.M: Mean Serum Range ± Standard Error of MeanBoroumand-Noughabi et al. BMC Cancer 2010, 10:275
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in serum was reported by Ichikura et al, only in older
male patients (over 50 years old)[20]. In contrast, Tsut-
sumi et al found not statistically significant differences
between serum level of sFasL in cancer patients com-
pared to normal individuals[22]. In the studied popula-
tion, serum level of sFasL was significantly lower in
tumoral than non-tumoral group. As the serum level of
sFasL could be influenced by both tumor cells production
and immune cells consumption of sFasL, the discrepan-
cies in the results may be explained by differences in
immune responses of patients. Varieties in clinicopatho-
logical features and diversities in socio-demographic
characteristics and ethnic background of the studied pop-
ulations may be another reason for controversial results.
Further validation sets focusing on cell expression of
FasL, serum level of sFasL and concurrent evaluation of
different aspects and impacts of immune response could
better elucidate the role of FasL/sFasL in gastric carcino-
genesis.
There are few reports about the relation between
serum level of soluble Fas and gastric cancer behaviour.
Liang  et al found a direct relation between increasing
sFas level with advance in the tumor grade and stage [21].
We observed a lower serum level of sFas in patients with
lymph node involvement. When tumor involves lymph
nodes, antitumor immunity will be provoked [33] which
may result in production of more FasL bearing immune
cells and subsequently sFas may be consumed more fol-
lowing binding and neutralizing these Fas Ligands.
Few controversial studies regarding the effects of con-
suming tobacco on Fas signalling pathways have been
published. Some have shown that tobacco increases
apoptosis through Fas signalling pathway[34,35], while
others reported the anti-apoptotic effects of tobacco on
the pathway[36,37]. We found higher levels of sFas in
tobacco users of the control group (p = 0.041), which is in
favour of apoptotic-inducing role of smoking. However,
as most of the cases were not tobacco users (53/62), stud-
Figure 1 Mean serum level of sFas (pg/ml) in intestinal-type gastric adenocarcinoma patients and different non-tumoral subgroups. The 
graph represents an increasing gradient for the mean serum level of sFas from normal mucosa toward gastric cancer (Kruskal-Wallis test, P < 0.001). 
Significant difference was observed between serum levels of sFas in each non-tumoral subgroup and cancer group.
 
 
P vs. Tumoral: <0.001
P vs. Precancerous Lesions: Not Significant
P vs. Tumoral: 0.009
P vs. Tumoral: <0.001
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ies with larger sample size and greater statistical power
are required to confirm this finding.
Conclusions
Fas/FasL system plays a crucial role in gastric carcinogen-
esis. Assessing the level of sFas in serum, may serve as a
biomarker for early diagnosis of gastric cancer. Further
studies that investigate both soluble and membranous
isoforms of Fas  gene products may provide valuable
information about correlations between serum level and
tissue expression of Fas gene products, helping in gaining
a better understanding of molecular basis of these
changes.
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